By: Kristopher May, OD; Deborah Ristvedt, DO; Leslie O’Dell, OD, FAAO; and Justin Schweitzer, OD, FAAO
This course has expired. You can still review the content but course credit is no longer available.
In this episode, faculty discuss the prevalence of glaucoma and how compliant patients are with their drop therapies. Faculty discuss why patients have difficulties with drops and how they impact their quality of life.
Supported by an unrestricted educational grant from Sight Sciences.
Upon completion of this activity, the participant should be able to:
Review the impact of patient compliance on conventional glaucoma treatment outcomes
Identify the importance of earlier intervention with the glaucoma patient, regardless of disease severity levels
Kristopher May, OD
Coldwater Vision Center
Coldwater, MS
Deborah Ristvedt, DO
Ophthalmologist Surgeon
Vance Thompson Vision
Bozeman, MT
Leslie O’Dell, OD, FAAO
Clinical Director
Medical Optometry America
York, PA
Justin Schweitzer, OD, FAAO
Vance Thompson Vision
Sioux Falls, SD
Kristopher May, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Sight Sciences. Speaker’s Bureau: Alcon, Bausch + Lomb, and Sight Sciences.
Deborah Ristvedt, DO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Dompe, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Oyster Point, Pharma, Sun Pharmaceutical Industries, Sight Sciences, and Tarsus. Speaker's Bureau: Allergan, Johnson & Johnson Vision, and Sight Sciences.
Justin Schweitzer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompé, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceutical Industries. Share/Stockholder: Equinox.
Christopher May, OD
Moderator
Coldwater Vision Center
Coldwater, MS
Deborah Ristvedt, DO
Vance Thompson Vision
Alexandria, MN
Leslie O'Dell, OD
Clinical Director of Medical Optometry America
York, PA
Justin Schweitzer, OD
Vance Thompson Vision
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Kristopher May, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Sight Sciences. Speaker’s Bureau: Alcon, Bausch + Lomb, and Sight Sciences.
Leslie O’Dell, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie and Sight Sciences.
Deborah Ristvedt, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos.
Justin Schweitzer, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompe, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceuticals. Share/Stockholder: Equinox.
The Evolve Medical Education or The Fundingsland Group staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Sight Sciences.